Skip to main content
. 2016 Feb 23;127(21):2587–2597. doi: 10.1182/blood-2015-07-659151

Figure 2.

Figure 2

Targeting MUC1-C downregulates β-catenin. (A-B) The WT and CRISPR RPMI8226 (A) and U266 (B) cells were subjected to immunoblot analysis with the indicated antibodies. (C-D) RPMI8226 (C) and U266 (D) cells were treated with 5 μM CP-2 or GO-203 for 48 hours. Lysates were immunoblotted with the indicated antibodies. (E-F) RPMI8226 (E) and U266 (F) cells were treated with control vehicle (DMSO) or 10 μM JW67 for 48 hours. The cells were analyzed for MYC mRNA levels by qRT-PCR (left). The results (mean ± SD of 3 determinations) are expressed as relative MYC mRNA levels as compared with that obtained for the control cells (assigned a value of 1). Lysates from the control (DMSO) and JW67-treated cells were immunoblotted with the indicated antibodies (right).